Summary
Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.
Hypertension itself does not manifest any symptoms, but direct damage can occur to various organs due to high blood pressure. In cases of hypertensive emergency (where blood pressure is higher than 180/110mmHg) patients have reported headaches, breathlessness or malaise due to heart failure and kidney failure. Whether symptomatic or asymptomatic, hypertension requires attention and appropriate changes in lifestyle or medical treatment
The marketed products landscape for hypertension comprises a wide range of treatment options, which includes angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta blockers, renin inhibitors, and diuretics. These are used both as monotherapy and combination therapy (including fixed-dose combinations), and the proportion of patients treated using the various therapy approaches varies from country to country.
The high prevalence of the disease is a substantial contributor to healthcare costs and is a major cause of morbidity. However, awareness of hypertension is low among physicians, patients, and the public, leading to a high level of undiagnosed and untreated cases.
Scope
The Asia-Pacific antihypertensive market will be valued at $27 billion in 2022, growing from $19.1 billion in 2015 at a CAGR of 5.1%. Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
- Will generics continue to dominate treatment?
- How do the elderly populations and their associated risk factors affect prevalence?
- What effect will the patent expirations of currently branded therapies have on market value?
The current anti-hypertensive therapeutics pipeline is weak, comprising 112 molecules in various stages of development, dominated by small molecules.
- Which molecular targets appear most frequently in the pipeline?
- Is there potential for the pipeline to address unmet needs within the anti-hypertensive market?
Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the high annual cost of therapy. Growth in market size is projected to vary considerably across the five assessed markets.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as aging population, metabolic disorders and high salt intake influence the market?
- Various drivers and barriers will influence the market over the forecast period.
- What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?
- Which factors are most likely to drive the market in these countries?
Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the anti-hypertensive market in terms of the dominant therapies, and their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the anti-hypertensive pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in hypertension clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Predict anti-hypertensive market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the anti-hypertensive deals landscape by analyzing trends in licensing and co-development deals.
'
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Introduction 9
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 11
2.5 Diagnosis 13
2.5.1 Office or Clinic Blood Pressure Monitoring 14
2.5.2 Automated Office Blood Pressure Measurement 14
2.5.3 Ambulatory Blood Pressure Monitoring 15
2.5.4 Home Blood Pressure Monitoring 15
2.5.5 Miscellaneous Methods 15
2.5.6 Diagnosis of Target Organ Damage 15
2.5.7 Diagnosis of Hypertension in Pregnancy 15
2.6 Prognosis 16
2.7 Disease Stage 17
2.8 Treatment Options 17
2.8.1 Treatment Algorithm 17
2.8.2 Pharmacological Treatment 18
2.8.3 Non-pharmacological Treatment 22
3 Marketed Products 24
3.1 Angiotensin II Receptor Antagonists 24
3.1.1 Losartan - Merck & Co 24
3.1.2 Olmesartan - Daiichi Sankyo 26
3.1.3 Olmesartan + Amlodipine + Hydrochlorothiazide - Daiichi Sankyo 27
3.1.4 Valsartan - Novartis 28
3.1.5 Telmisartan - Boehringer Ingelheim 29
3.1.6 Azilsartan Medoxomil - Takeda 30
3.2 Calcium Channel Blockers 31
3.2.1 Amlodipine - Pfizer 31
3.3 Renin Inhibitors 32
3.3.1 Aliskiren - Novartis 32
3.4 Angiotensin Converting Enzyme Inhibitors 33
3.4.1 Ramipril - Sanofi 33
3.5 Beta Blockers 33
3.5.1 Carvedilol - GlaxoSmithKline 33
3.6 Multiple Drug Class Combinations 34
3.6.1 Perindopril Arginine + Amlodipine Besylate - Les Laboratoires Servier 34
3.6.2 Amlodipine + Valsartan - Novartis 35
3.7 Comparative Efficacy and Safety of Marketed Products 36
4 Pipeline Analysis 38
4.1 Overview 38
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 39
4.3 Pipeline by Molecular Target 41
4.4 Promising Pipeline Candidates 43
4.4.1 CS-3150 43
5 Clinical Trial Analysis 45
5.1 Failure Rate 45
5.1.1 Overall Failure Rate 45
5.1.2 Failure Rate by Phase and Molecule Type 46
5.1.3 Failure Rate by Phase and Molecular Target 47
5.2 Clinical Trial Duration 48
5.2.1 Clinical Trial Duration by Molecule Type 48
5.2.2 Clinical Trial Duration by Molecular Target 49
5.3 Clinical Trial Size 50
5.3.1 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 50
5.3.2 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 52
5.4 Competitive Clinical Trials Metrics Analysis 54
6 Multi-Scenario Forecast 56
6.1.1 Geographical Markets 56
6.1.2 Asia-Pacific Market 56
6.2 India 59
6.2.1 Treatment Use Patterns 59
6.2.2 Annual Cost of Therapy 60
6.2.3 Market Size 60
6.3 China 61
6.3.1 Treatment Use Patterns 61
6.3.2 Annual Cost of Therapy 62
6.3.3 Market Size 63
6.4 Australia 64
6.4.1 Treatment Use Patterns 64
6.4.2 Annual Cost of Therapy 65
6.4.3 Market Size 66
6.5 South Korea 67
6.5.1 Treatment Usage Patterns 67
6.5.2 Annual Cost of Therapy 69
6.5.3 Market Size 70
6.6 Japan 70
6.6.1 Treatment Use Patterns 70
6.6.2 Annual Cost of Therapy 71
6.6.3 Market Size 72
7 Drivers and Barriers 74
7.1 Drivers 74
7.1.1 Increasing Aging Populations to Increase Prevalence 74
7.1.2 Increasing Overweight and Obese Population 74
7.1.3 Increase in Daily Sodium Intake 74
7.1.4 Sedentary Lifestyle or Less Physical Activity 75
7.1.5 High Prevalence of Smoking and Alcoholism 75
7.1.6 Diversified Healthcare Reform to Boost Market Growth 76
7.2 Barriers 76
7.2.1 Weak Pipeline and Widespread Usage of Generic Drugs 76
7.2.2 Non-pharmacological First-Line Treatment 76
7.2.3 Lack of Awareness of the Disease Condition 76
8 Deals and Strategic Consolidations 77
8.1 Licensing Deals 77
8.1.1 Deals by Region and Value 77
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 78
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 79
8.1.4 Key Licensing Deals 81
8.2 Co-development Deals 82
8.2.1 Deals by Region and Value 83
8.2.2 Deal Value by Stage of Development, Molecule Type, and Molecular Target 84
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 84
8.2.4 Key Co-development Deals 85
9 Appendix 87
9.1 All Pipeline Drugs by Stage of Development 87
9.1.1 Discovery 87
9.1.2 Preclinical 87
9.1.3 Investigational New Drug/ Clinical Trial Authorization-Filed 89
9.1.4 Phase I 90
9.1.5 Phase II 91
9.1.6 Phase III 91
9.1.7 Pre-registration 93
9.2 Market Forecasts to 2022 93
9.2.1 Asia-Pacific 93
9.2.2 India 94
9.2.3 China 94
9.2.4 Australia 95
9.2.5 South Korea 95
9.2.6 Japan 96
9.3 Reference 96
9.4 Abbreviations 105
9.5 Research Methodology 107
9.5.1 Secondary Research 107
9.5.2 Marketed Product Profiles 107
9.5.3 Late-Stage Pipeline Candidates 107
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 108
9.5.5 Product Competitiveness Framework 108
9.5.6 Pipeline Analysis 108
9.5.7 Forecasting Model 109
9.5.8 Deals Data Analysis 110
9.6 Contact Us 110
9.7 Disclaimer 110
1.1 List of Tables
Table 1: Anti-hypertensive Therapeutics, Prevalence Rate 11
Table 2: Anti-hypertensive Therapeutics, Definitions of Hypertension by Office and Out-of-Office Blood Pressure Levels (mmHg) 14
Table 3: Anti-hypertensive Therapeutics, Proposal for Outcome-Driven Reference Values for Ambulatory Blood Pressure Measurement (mmHg) 15
Table 4: Anti-hypertensive Therapeutics, Blood Pressure Stages in Adults (mmHg) 17
Table 5: Anti-hypertensive Therapeutics, Compelling and Possible Contra-indications of Anti-hypertensive Drugs 22
Table 6: Anti-hypertensive Therapeutics, Lifestyle Measures and Recommendations 23
Table 7: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Discovery, 2016 87
Table 8: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016 87
Table 9: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Investigational New Drug, 2016 89
Table 10: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase I, 2016 90
Table 11: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase-II, 2016 91
Table 12: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase III, 2016 91
Table 13: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016 93
Table 14: Anti-hypertensive Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022 93
Table 15: Anti-hypertensive Therapeutics Market, India, Market Forecast, 2015-2022 94
Table 16: Anti-hypertensive Therapeutics Market, China, Market Forecast, 2015-2022 94
Table 17: Anti-hypertensive Therapeutics Market, Australia, Market Forecast, 2015-2022 95
Table 18: Anti-hypertensive Therapeutics Market, South Korea, Market Forecast, 2015-2022 95
Table 19: Anti-hypertensive Therapeutics Market, Japan, Market Forecast, 2015-2022 96
Table 20: Abbreviations 105
1.2 List of Figures
Figure 1: Anti-hypertensive Therapeutics, Global, Hypertension Prevalence Rate (%), 2009-2012 10
Figure 2: Anti-hypertensive Therapeutics, Physiological Mechanism of Renin-Angiotensin-Aldosterone System 13
Figure 3: Anti-hypertensive Therapeutics: Blood Pressure Measurements and Examination of a Patient to Detect Hypertension 16
Figure 4: Anti-hypertensive Therapeutics, Treatment Algorithm of Hypertension 18
Figure 5: Anti-hypertensive Therapeutics, Combination Therapy Strategies for Blood Pressure Reduction 21
Figure 6: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Hypertension 37
Figure 7: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Pediatrics for the Treatment of Hypertension 37
Figure 8: Anti-hypertensive Therapeutics Market, Global, Pipeline, 2016 40
Figure 9: Anti-hypertensive Therapeutics Market, Global, Pipeline by Molecular Target, 2016 42
Figure 10: Anti-hypertensive Therapeutics, Global, Pipeline by Molecular Target and Stage of Development, 2016 43
Figure 11: Anti-hypertensive Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2016 46
Figure 12: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006-2015 47
Figure 13: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target (%), 2006-2015 48
Figure 14: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2015 49
Figure 15: Anti-hypertensive Therapeutics, Global, Clinical Trial Duration by Molecular Target, 2006-2015 50
Figure 16: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Type, 2006-2015 51
Figure 17: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2015 52
Figure 18: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecule Type, 2006-2015 53
Figure 19: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecular Target, 2006-2015 54
Figure 20: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 55
Figure 21: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 55
Figure 22: Anti-hypertensive Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2015-2022 58
Figure 23: Anti-hypertensive Therapeutics Market, India, Treatment Patterns (million), 2015-2022 59
Figure 24: Anti-hypertensive Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022 60
Figure 25: Anti-hypertensive Therapeutics Market, India, Market Size ($bn), 2015-2022 61
Figure 26: Anti-hypertensive Therapeutics Market, China, Treatment Patterns (million), 2015-2022 62
Figure 27: Anti-hypertensive Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022 63
Figure 28: Anti-hypertensive Therapeutics Market, China, Market Size ($bn), 2015-2022 64
Figure 29: Anti-hypertensive Therapeutics Market, Australia, Treatment Patterns (million), 2015-2022 65
Figure 30: Anti-hypertensive Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022 66
Figure 31: Anti-hypertensive Therapeutics Market, Australia, Market Size ($bn), 2015-2022 67
Figure 32: Anti-hypertensive Therapeutics Market, South Korea, Treatment Patterns (million), 2015-2022 68
Figure 33: Anti-hypertensive Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022 69
Figure 34: Anti-hypertensive Therapeutics Market, South Korea, Market Size ($bn), 2015-2022 70
Figure 35: Anti-hypertensive Therapeutics Market, Japan, Treatment Patterns (million), 2015-2022 71
Figure 36: Anti-hypertensive Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022 72
Figure 37: Anti-hypertensive Therapeutics Market, Japan, Market Size ($bn), 2015-2022 73
Figure 38: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016 78
Figure 39: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016 79
Figure 40: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016 80
Figure 41: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016 80
Figure 42: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2016 81
Figure 43: Anti-hypertensive Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2016 83
Figure 44: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016 84
Figure 45: Anti-hypertensive Therapeutics, Global, Co-development Deals by Phase and Mechanism of Action, 2006-2016 85
